Scope and Claims Analysis for US Patent 8,455,472: Method Claims for Triglyceride Lowering on Stable Statin Therapy Using Ethyl Eicosapentaenoate
US Patent 8,455,472 is a US method-of-treatment patent with claims tightly scoped to a specific patient-treatment context (stable statin therapy; baseline fasting triglycerides in a defined range) and a fixed dosing regimen (about 4 capsules/day; capsule fill containing ~900 mg to 1 g ethyl eicosapentaenoate with ≤3% docosahexaenoic acid (DHA) or its esters by weight of total fatty acids) for at least ~12 weeks. The independent claim is effectively a “use of an ethyl eicosapentaenoate capsule composition” framed as a triglyceride-lowering method in statin-treated subjects.
The claim set also adds narrower dependent claim filters around LDL-C baseline, % lipid reductions, capsule compositional ranges of other ethylated fatty acids, gelatin shell, specific statins, and clinical endpoints including Apolipoprotein B and Lp-PLA2.
What does US Patent 8,455,472 claim, and what is the core method scope?
Core independent claim (Claim 1) recites a method of lowering triglycerides using a defined product and regimen in a defined population:
-
Population condition
- Subject on stable statin therapy
- Baseline fasting triglycerides: about 200 mg/dL to about 500 mg/dL
-
Treatment regimen
- Administer about 4 capsules per day
- Each capsule comprises:
- about 900 mg to about 1 g ethyl eicosapentaenoate (ethyl-EPA)
- not more than about 3% DHA or its esters by weight of all fatty acids present
- Duration: at least about 12 weeks
Functional scope
- The claim is not written as “reduces triglycerides to X target,” but it is operationally a triglyceride-lowering method in the specified clinical context. The later dependent claims quantify lipid reduction and expand endpoints.
Key infringement-relevant constraints
- A clinical program that treats a broader triglyceride range, uses different dosing (less than “about 4 capsules/day”), uses lower ethyl-EPA per capsule, uses higher DHA content, or treats fewer than 12 weeks would fall outside the claim boundaries as written.
How do dependent claims narrow the triglyceride method and add lipid endpoints?
Which LDL-C baseline thresholds are claimed? (Claims 2, 14, 19)
- Claim 2: baseline LDL-C ~40 mg/dL to ~115 mg/dL
- Claim 14: baseline BMI not greater than 45 kg/m²
- Claim 19: adds a statin-specific version (rosuvastatin) and requires performance vs a statin-treated comparator not receiving the claimed capsules.
These create narrower target cohorts. If a generic or competitor’s studied population has LDL-C outside the range, they can argue non-infringement for dependent claims requiring that baseline feature.
What % reductions are claimed? (Claims 4–8, 15–17, 19)
The patent builds a performance ladder:
- Claim 4: daily for the period effects:
- at least a 5% reduction in fasting triglycerides, and
- a reduction in LDL-C
- Claim 5: at least a 5% reduction in LDL-C
- Claim 6: at least a 10% reduction in triglycerides
- Claim 7: at least a 15% reduction in triglycerides
- Claim 8 (linked to Claim 7): at least a 15% triglyceride reduction plus reductions in:
- Apolipoprotein B
- Total cholesterol
- Lp-PLA2 (lipoprotein associated phospholipase A2)
The dependent claims escalate evidentiary strength. They require outcome data that, in litigation, typically forces the accused method to match both population and achieved endpoints.
What placebo-controlled endpoint claims exist? (Claims 15–17, 19)
-
Claim 15: administer 4 capsules/day for 12 weeks to effect at least 15% triglyceride reduction and reduction in LDL-C vs placebo-controlled subject
-
Claim 16: at least 5% LDL-C reduction vs placebo
-
Claim 17: at least 5% apolipoprotein B reduction vs placebo
-
Claim 19: rosuvastatin statin therapy + specified fill material + administer 4/day for the period to effect:
- at least 15% triglyceride reduction
- at least 5% LDL-C reduction
- compared to a subject on stable statin therapy who did not receive the claimed capsules
This matters for defense: if an accused regimen is compared to a different comparator design (active control vs placebo, different endpoint definitions, different baseline ranges), dependent claims may be harder to map directly to trial results used in the infringement analysis.
What is claimed about capsule composition beyond ethyl-EPA and DHA? (Claims 9–10)
High ethyl-EPA purity threshold
- Claim 9: each capsule comprises at least about 95% ethyl eicosapentaenoate by weight of all fatty acids
This is a major narrowing factor. A competing ethyl-EPA product that includes additional fatty acid components but does not hit the “≥95% ethyl-EPA by weight of all fatty acids” condition would miss this dependent claim.
Specific compositional ranges of additional ethylated fatty acids
- Claim 10 adds granular compositional limitations, including (percent by weight of all fatty acids):
- ethyl octadecatetraenoate: 0.22% to 0.4%
- ethyl nonaecapentaenoate: 0.075% to 0.2%
- ethyl arachidonate: 0.25% to 0.40%
- ethyl eicosapentaenoate: 0.3% to 0.4%
- ethyl heneicosapentaenoate: 0.075% to 0.25%
Why this matters
- These detailed ratios are likely tied to a specific purified or standardized ethyl-EPA product profile. They create a compositional “fingerprint” that competitors must match if they want to avoid infringement of dependent claim features requiring these ranges.
Potential internal tension to flag for claim construction
- Claim 9 says each capsule has ≥95% ethyl eicosapentaenoate by weight of all fatty acids.
- Claim 10 includes a range for ethyl eicosapentaenoate that appears inconsistent with “≥95%” if interpreted literally as “% of all fatty acids.” In typical patent drafting, ranges are unambiguous, but the provided claim text suggests either (a) Claim 10 may be transcribed incompletely or (b) “about 0.3% to about 0.4% ethyl eicosatetraenoate” may be a typographical mismatch for ethyl-eicosapentaenoate versus another species.
For an infringement analysis, this kind of issue can affect claim construction and validity arguments, depending on the intrinsic record. The scope analysis here is limited to the claim text provided.
What does the patent say about capsule dosage form and shell? (Claims 11–12)
- Claim 11: capsules have a shell
- Claim 12: the shell comprises gelatin
This narrows method infringement to dosing forms that use a gelatin shell in the claimed method context. If a competitor markets ethyl-EPA in a non-gelatin shell format, dependent claims 11–12 may be easier to design around, though Claim 1 itself is not limited to gelatin.
How do the claims tie triglyceride lowering to specific statins? (Claims 13 and 18–19)
General statin selection
- Claim 13: statin selected from:
- atorvastatin
- rosuvastatin
- simvastatin
Rosuvastatin-specific dependent claim
- Claim 18: where the statin comprises rosuvastatin
- Claim 19: combines rosuvastatin with the performance metrics and the specified fill material, comparing against a statin-only comparator.
In practice, this means:
- A competitor could still fall under Claim 1 for other statins unless limited by Claim 13’s dependent coverage, but Claim 13 creates a narrower pathway for enforcement if the accused regimen uses one of those three statins.
What is the practical coverage profile for US Patent 8,455,472? (Claim mapping summary)
Coverage matrix (from the claim text provided)
| Claim |
Anchor population |
Regimen |
Capsule composition constraints |
Clinical endpoints |
| 1 |
Stable statin; baseline fasting TG 200–500 mg/dL |
~4 capsules/day; ≥12 weeks |
~900 mg–1 g ethyl-EPA/capsule; ≤3% DHA by wt of all fatty acids |
“lowering triglycerides” (functional) |
| 2 |
+ baseline LDL-C 40–115 mg/dL |
same |
same |
implied |
| 3 |
+ (depends on 2) |
same |
same |
requires effect on serum LDL-C |
| 4 |
+ (depends on 3) |
same |
same |
≥5% fasting TG reduction and LDL-C reduction |
| 5 |
+ (depends on 3) |
same |
same |
≥5% LDL-C reduction |
| 6 |
+ (depends on 3) |
same |
same |
≥10% TG reduction |
| 7 |
+ (depends on 3) |
same |
same |
≥15% TG reduction |
| 8 |
+ (depends on 7) |
same |
same |
includes ApoB, total cholesterol, Lp-PLA2 |
| 9 |
same |
same |
≥95% ethyl-EPA by wt of all fatty acids |
implied |
| 10 |
same |
same |
specific ethylated fatty acid range profile |
implied |
| 11–12 |
same |
same |
gelatin shell |
implied |
| 13 |
same |
same |
statin in atorvastatin/rosuvastatin/simvastatin group |
implied |
| 14 |
same |
same |
same |
baseline BMI ≤45 |
| 15–17 |
same |
12 weeks |
same |
placebo-controlled: ≥15% TG + LDL-C reduction; then LDL-C and ApoB metrics |
| 18–19 |
rosuvastatin |
same |
same + comparator |
rosuvastatin comparator and performance thresholds |
Which design-arounds reduce risk of infringing US 8,455,472 (based on claim boundaries)?
This is a practical risk checklist derived directly from the claim limitations:
-
Population selection
- Avoid treating patients with baseline fasting triglycerides 200–500 mg/dL under stable statin therapy as defined.
- Avoid baseline LDL-C 40–115 mg/dL if trying to defeat dependent claims.
-
Dose regimen
- Move away from ~4 capsules/day.
- Use shorter exposure than 12 weeks if the method claim requires “at least about 12 weeks.”
-
Capsule content
- If DHA (or DHA esters) exceeds ~3% by weight of total fatty acids, you miss Claim 1’s cap.
- Reduce per-capsule ethyl-EPA outside the ~900 mg to ~1 g band.
-
Composition fingerprint
- Do not match the “≥95% ethyl-EPA” requirement.
- Avoid matching the detailed minor-component ranges in Claim 10.
-
Dosage form
- Use non-gelatin shells to avoid dependent Claim 12.
-
Statin context
- While Claim 1 is anchored to stable statin therapy generally, dependent claims (13, 18–19) add constraints to specific statins and comparative designs.
Where does this patent sit in the Orange Book and FDA exclusivity map (and how do you read it)?
The provided prompt does not include the Orange Book listing, application number, NDA/BLA, dosage form, or reference product. Without those identifiers, a complete Orange Book status map cannot be produced from the claim text alone.
Still, the claim style (method-of-treatment with dosage regimen and endpoints) strongly indicates this patent is designed to attach to a specific branded capsule regimen of ethyl-EPA used in statin-treated hypertriglyceridemic patients. In litigation, the key question becomes whether an accused label and clinical study replicate:
- the same baseline TG cohort
- the same dosing and duration
- the same product composition profile (ethyl-EPA and DHA constraints)
For Paragraph IV ANDA or label carve-outs, the enforcement theory typically targets whether the proposed generic’s intended use and label instructions would infringe the claimed method when used as directed.
What would a generic or biosimilar-like challenge theory look like for these specific claims?
Even though this is an ethyl-EPA capsule composition method patent (not biologic-like), the litigation logic for US drug patents generally follows three tracks:
-
Non-infringement by label and practice
- Argue that the proposed label does not instruct the claimed “stable statin therapy + TG 200–500 mg/dL + ~4 capsules/day + ≥12 weeks” approach.
- Argue formulation differences: DHA content >3%, ethyl-EPA per capsule outside the range, or different fatty acid profile not matching Claim 9/10.
-
Non-infringement by achieved outcomes
- Dependent claims tied to % changes (TG and LDL-C, ApoB, Lp-PLA2) often require a showing that the method as practiced results in those endpoints in the claimed cohort.
- If clinical evidence differs materially, dependent claim mapping weakens.
-
Invalidity against claim boundaries
- Compositional subranges and endpoint thresholds can be attacked for lack of novelty or obviousness if prior art disclosed similar ethyl-EPA dosing in statin-treated subjects with similar TG/LDL endpoints.
- The narrow “minor component fingerprint” in Claim 10 is a double-edged sword: it narrows infringement but increases the risk that prior art already disclosed standardized mixtures.
The provided prompt includes no prior art citations, prosecution history, or litigation docket for 8,455,472, so a precise freedom-to-operate or validity assessment cannot be completed to professional standards from claim text alone.
Key takeaways
- US 8,455,472 is centered on a method of lowering triglycerides in statin-stable subjects with baseline fasting TG 200–500 mg/dL using a fixed ethyl-EPA capsule regimen: ~4 capsules/day for ≥12 weeks, with capsule fill containing ~900 mg to ~1 g ethyl-EPA and ≤3% DHA (or esters) by weight of total fatty acids.
- Dependent claims add baseline LDL-C and BMI, and require measurable lipid reductions (≥5% LDL-C, ≥10% TG, ≥15% TG) and additional biomarkers (ApoB, Lp-PLA2).
- Composition-dependent coverage tightens further with ≥95% ethyl-EPA and detailed minor fatty acid ethylated component ranges.
- Dosage form dependence exists for gelatin shells, and treatment context is reinforced for atorvastatin/rosuvastatin/simvastatin plus a rosuvastatin-specific performance claim with specified comparator framing.
FAQs
-
Does US 8,455,472 require showing a specific triglyceride percent reduction to infringe Claim 1?
Claim 1 is framed as a “method of lowering triglycerides” without an explicit numeric reduction threshold; numeric thresholds appear in dependent claims.
-
Can a competitor avoid infringement by using a different number of capsules per day than “about 4 capsules”?
Claim 1 is dose-count limited via “about 4 capsules per day,” so deviating materially from that regimen is a key design-around lever.
-
What is the most composition-critical limitation in this patent?
The combination of ~900 mg–1 g ethyl-EPA per capsule and ≤3% DHA (or esters) by weight of all fatty acids is the core formulation constraint.
-
Are gelatin shells required for all claims?
No. Gelatin is required only in dependent claims tied to shell composition (Claims 11–12).
-
Which biomarkers are explicitly required in the narrower dependent claims?
Dependent Claim 8 requires reductions in Apolipoprotein B, total cholesterol, and Lp-PLA2 (in addition to the ≥15% triglyceride reduction).
References
- US Patent No. 8,455,472 (claims provided in prompt text).
